CELCUITY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.82 USD | -1.00% |
|
-5.24% | +1.72% |
| May. 31 | Needham Trims Price Target on Celcuity to $23 From $24, Maintains Buy Rating | MT |
| May. 30 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 9.76M | Capitalization | 525M |
|---|---|---|---|---|---|
| Net income 2024 * | -94M | Net income 2025 * | -134M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 130M | Net cash position 2025 * | - | EV / Sales 2025 * | 53.8 x |
| P/E ratio 2024 * |
-5.46
x | P/E ratio 2025 * |
-4.4
x | Employees | 55 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celcuity Inc.
More recommendations
More press releases
| 1 day | -1.00% | ||
| 1 week | -5.24% | ||
| Current month | -6.20% | ||
| 1 month | -16.13% | ||
| 3 months | -14.97% | ||
| 6 months | -0.40% | ||
| Current year | +1.72% |
1 week
14.21
16.78
1 month
14.2119.73
Current year
13.4822.19
1 year
8.3922.19
3 years
4.8133.01
5 years
4.0333.01
10 years
4.0333.01
| Managers | Title | Age | Since |
|---|---|---|---|
Lance Laing
FOU | Founder | 62 | 11-12-31 |
Brian Sullivan
CEO | Chief Executive Officer | 62 | 11-12-31 |
Vicky Hahne
DFI | Director of Finance/CFO | 57 | 17-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Brian Sullivan
CEO | Chief Executive Officer | 62 | 11-12-31 |
Richard Nigon
BRD | Director/Board Member | 76 | 16-12-31 |
David Dalvey
BRD | Director/Board Member | 65 | 14-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.46% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 14.83 | -0.94% | 175,782 |
| 24-06-03 | 14.97 | -5.25% | 209,022 |
| 24-05-31 | 15.8 | +4.64% | 246,228 |
| 24-05-30 | 15.1 | +1.75% | 1,948,472 |
| 24-05-29 | 14.84 | -2.11% | 80,916 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotes
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.83
USD
Average target price
28.76
USD
Spread / Average Target
+93.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.72% | 525M | |
| +16.73% | 121B | |
| +13.04% | 107B | |
| -5.80% | 24.82B | |
| +1.69% | 22.48B | |
| -10.09% | 18.32B | |
| -40.52% | 16.33B | |
| -14.00% | 15.31B | |
| +1.18% | 14.08B | |
| +24.18% | 11.74B |
- Stock Market
- Equities
- CELC Stock
